NERV Stock Overview
A clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Minerva Neurosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.15 |
| 52 Week High | US$13.49 |
| 52 Week Low | US$2.07 |
| Beta | 0.17 |
| 11 Month Change | -12.60% |
| 3 Month Change | -23.21% |
| 1 Year Change | -63.18% |
| 33 Year Change | -70.30% |
| 5 Year Change | -95.63% |
| Change since IPO | -95.56% |
Recent News & Updates
Recent updates
Minerva says FDA declined to accept marketing application for schizophrenia drug
Oct 17Minerva Neurosciences: Biotech On The Move
Aug 29Minerva stock rises on filing for FDA approval of schizophrenia therapy
Aug 22We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely
Jun 22
Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?
Jan 26Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation
Oct 02Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares
Mar 03What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition
Jan 27We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate
Dec 23
A Potential Trade Arises On Minerva
Dec 09A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns
Nov 18Minerva Neurosciences EPS beats by $0.03
Nov 02Shareholder Returns
| NERV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 1.4% | 4.3% | 1.6% |
| 1Y | -63.2% | 18.8% | 32.3% |
Return vs Industry: NERV underperformed the US Biotechs industry which returned 18% over the past year.
Return vs Market: NERV underperformed the US Market which returned 32.4% over the past year.
Price Volatility
| NERV volatility | |
|---|---|
| NERV Average Weekly Movement | 6.6% |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: NERV has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: NERV's weekly volatility has decreased from 14% to 7% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 9 | Remy Luthringer | www.minervaneurosciences.com |
Minerva Neurosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson’s disease and other neurodegenerative disorders. The company has a license agreement with Mitsubishi Tanabe Pharma Corporation to develop, sell, and import roluperidone globally excluding Asia.
Minerva Neurosciences, Inc. Fundamentals Summary
| NERV fundamental statistics | |
|---|---|
| Market cap | US$15.18m |
| Earnings (TTM) | -US$3.31m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-4.5x
P/E RatioIs NERV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| NERV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$12.40m |
| Gross Profit | -US$12.40m |
| Other Expenses | -US$9.09m |
| Earnings | -US$3.31m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -276.9% |
How did NERV perform over the long term?
See historical performance and comparison